

9. (Amended) A compound according to claim 1 for use as a medicament for the modulation of angiogenesis wherein said compound increases the export of cholesterol out of peripheral cells through the increased abundance of HDL particles resulting in the modulation of caveolin-1.

11. (Amended) A compound according to claim 1 for use as a medicament for the modulation of angiogenesis wherein said compound decreases the production of cholesterol-rich VLDL particles by the liver.

13. (Amended) A compound according to claim 1 for use as a medicament for the modulation of angiogenesis wherein said compound influences abundance and/or activity of caveolin-1, eNOS, Hsp90 or calmodulin.

21. (Amended) A compound according to claim 13 for use as a medicament for the modulation of angiogenesis, which is able to trap the endogenous caveolin-1 preventing its binding to the endothelial isoform nitric oxide synthase (eNOS).

22. (Amended) A compound according to claim 13 for use as a medicament for the modulation of angiogenesis which is a nucleic acid encoding the partial or total amino acid sequence of eNOS or the eNOS sequence deleted or mutated in the active caveolin binding site or an analogue thereof which can increase the concentration of unbound (activated) eNOS.

27. (Amended) A pharmacological composition comprising a compound according to claim 1 or a pharmacologically acceptable derivative thereof for the stimulation or inhibition of angiogenesis.

*BS  
CRA*  
tumor growth and metastatic diseases, ischemic heart and peripheral vascular diseases including cerebral diseases and wound healing.

31. (Amended) Method to manufacture a medicament for the modulation of angiogenesis comprising a compound according to claim 1.

32. (Amended) Method of treating a subject in the need of influencing angiogenesis by administering an angiogenesis-modulating-compound according to claim 1 in a sufficient concentration able to modulate angiogenesis within this subject.

*BS*  
33. (Amended) Use of a compound according to claim 1 for the modulation of the cholesterol metabolism in a cell in vitro, in vivo or ex vivo.

34. (Amended) Use of a compound according to claim 1 for the modulation of the expression of caveolin-1 in a cell in vitro, in vivo or ex vivo. 25

35. (Amended) Use of a compound according to claim 1 for the modulation of the expression of eNOS in a cell in vitro, in vivo or ex vivo.

36. (Amended) Use of a compound according to claim 1 for the modulation of the expression of calmodulin in a cell in vitro, in vivo or ex vivo. 30

37. (Amended) Use of a compound according to claim 1 for the expression of Hsp90 in a cell in vitro, in vivo or ex vivo.